|1.||De Ponti, F: 2 articles (02/2004 - 04/2003)|
|2.||Tonini, M: 2 articles (02/2004 - 04/2003)|
|3.||Chen, Hui: 1 article (11/2015)|
|4.||Li, Huqun: 1 article (11/2015)|
|5.||Xu, Mingzhen: 1 article (11/2015)|
|6.||Li, Weiyong: 1 article (11/2015)|
|7.||Zhou, Ying: 1 article (11/2015)|
|8.||Ni, Yang: 1 article (11/2015)|
|9.||Sattar, Haseeb: 1 article (11/2015)|
|10.||He, Xiaomeng: 1 article (11/2015)|
03/01/2007 - "In conclusion, levosulpiride is an effective and safe drug in the treatment of dysmotility-like functional dyspepsia and non-erosive reflux disease."
03/01/2007 - "The study was conducted as a prospective, open-label, multicenter design in 342 patients with dysmotility-like functional dyspepsia (n=279) and nonerosive reflux disease (n=63), who received levosulpiride 25 mg 3 times daily orally for 4 weeks. "
02/01/1998 - "This study was undertaken to investigate the effects of levosulpiride on dyspeptic symptoms and gastric motor function in a group of patients with functional dyspepsia showing delayed gastric emptying. "
07/01/1996 - "Levosulpiride in functional dyspepsia: a multicentric, double-blind, controlled trial."
10/01/2010 - "[Levosulpiride in the management of functional dyspepsia and delayed gastric emptying]."
|2.||Somatoform Disorders (Somatoform Disorder)
02/01/1995 - "Several clinical studies indicate that levosulpiride has therapeutic efficacy in depressive and somatoform disorders, as well as in schizophrenic patients with predominant negative features. "
01/01/2003 - "Seventy-four patients with SDs diagnosed according to ICD-10 and DSM-IIIR criteria by means of the Comprehensive International Schedule for Somatoform Disorders-Somatoform Disorders Schedule (CISSD-SDS) were treated for 4 weeks either with levosulpiride (50 mg b.i.d.) or placebo, under double-blind, cross-over conditions. "
01/01/2003 - "Levosulpiride in somatoform disorders: A double-blind, placebo-controlled cross-over study."
02/01/1995 - "Levosulpiride is the levorotatory enantiomer of sulpiride, a substituted benzamide indicated as an antipsychotic, antidepressant, antiemetic and antidyspeptic drug, as well as for the treatment of somatoform disorders. "
|3.||Peptic Esophagitis (Reflux Esophagitis)
03/01/2007 - "The objective of this study was to assess the effectiveness and safety of levosulpiride in patients with dysmotility-like functional dyspepsia including nonerosive reflux esophagitis in conditions of daily practice. "
09/01/1992 - "[The efficacy of the omeprazole-levosulpiride combination in the therapy of distal reflux esophagitis]."
09/01/1992 - "The therapeutic effectiveness of levosulpiride associated with omeprazole versus omeprazole alone in the reflux esophagitis has been evaluated. "
|4.||Schizophrenia (Dementia Praecox)
07/01/1996 - "Significant improvement was recorded for all symptoms at days 10 and 28 in all groups (p < 0.001), but levosulpiride was significantly (p < 0.01) superior to domperidone, metoclopramide and placebo both in the overall clinical improvement scale as well as in a subgroup of symptoms (postprandial bloating, epigastric pain, heartburn). "
|7.||Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)
|8.||Cyclooxygenase 2 (Cyclooxygenase-2)
|10.||Dopamine D2 Receptors (Dopamine D2 Receptor)
|2.||Drug Therapy (Chemotherapy)